Soligenix
29 Emmons Drive
Suite C-10
Princeton
New Jersey
08540
United States
Tel: 609-538-8200
Fax: 609-452-6467
Website: http://www.soligenix.com/
418 articles about Soligenix
-
Soligenix Taps a New CFO
6/20/2016
-
Soligenix Announces Presentation Of Phase 2 Oral Mucositis Clinical Trial Results At The 2016 Multinational Association For Supportive Care In Cancer Conference
6/6/2016
-
Soligenix Release: FDA Grants Soligenix "Fast Track" Designation For SGX943 For The Treatment Of Melioidosis
5/31/2016
-
Soligenix To Present At The 2016 Marcum MicroCap Conference
5/26/2016
-
Soligenix Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine
5/25/2016
-
Soligenix Announces Recent Accomplishments And First Quarter 2016 Financial Results
5/12/2016
-
Soligenix Receives Additional National Institute of Allergy And Infectious Diseases (NIAID) Funding To Advance Development Of Heat Stable Ricin Vaccine
5/5/2016
-
Soligenix Announces Issuance Of New Patents For Dusquetide
4/14/2016
-
Soligenix Announces Publication Of Preclinical Efficacy Results With Dusquetide In Infectious Disease
3/29/2016
-
Soligenix Announces Recent Accomplishments And Year-End 2015 Financial Results
3/24/2016
-
Soligenix Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine
3/17/2016
-
Soligenix To Present At Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
2/2/2016
-
Soligenix Provides 2016 Business Outlook
1/26/2016
-
Vista Partners Updates Coverage On Soligenix (Ticker: SNGX); Price Target $7.00
12/22/2015
-
SciClone Pharmaceuticals, Inc. To Pursue Development Of SGX942 In China Following Soligenix' Report Of Positive Phase 2 Preliminary Results In Oral Mucositis
12/21/2015
-
Soligenix Will Host A Conference Call To Update Shareholders On Recent Positive Clinical Results And Company Development Milestones
12/16/2015
-
Soligenix Announces Positive Preliminary Results From Its Phase 2 Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
12/16/2015
-
Soligenix Announces Initiation Of Its Pivotal Phase 3 Clinical Trial Of SGX301 (Synthetic Hypericin) For The Treatment Of Cutaneous T-Cell Lymphoma
12/14/2015
-
Soligenix Receives $490,000 In Non-Dilutive Financing From New Jersey's Technology Business Tax Certificate Transfer Program
12/9/2015
-
Soligenix Provides Clinical Program Updates For December 2015
12/4/2015